Bites up, but dog count dips in corpn survey
An RTI reply had in 2021 placed the number at 53,826 in 2020, while a 2012 survey had recorded 47,573 dogs. Dog bite cases within corporation limits reached 14,130 by Nov 2024, the highest since 2018, pointing to the urgent need for effective stray management. Corporation officials, however, insist that the March 2025 enumeration is the most accurate to date, as it was conducted using scientific methods in collaboration with Worldwide Veterinary Service (WVS) and animal welfare NGO Seeshah's Kennel Foundation. The new figure for Madurai is also lower than that of Trichy corporation, which recently published a 2025 survey placing its stray dog population at 43,767. City health officer (CHO) P Indhira told TOI that Madurai's survey was carried out in all 100 wards covering five city zones. The initial groundwork and mapping were done between March 5 and 14, after which 200 student volunteers and corporation staff were trained for field enumeration. From March 17 to 23, around 300 surveys were conducted, with data collected from an average of 31% of roads in each ward. The methodology included sampling, grid mapping, training of enumerators, and multi-stage data collection. "We have done a proper survey and this is the most scientific survey. The dog count may have decreased after Covid pandemic due to decrease in number of feeders," said the CHO.The demographic breakdown revealed that 15% of the dogs were puppies (under three months), and 85% adults. Among the adults, 83% were aged over one year, and 17% were juveniles between 4 and 11 months. Male dogs accounted for 65% of the population and females, 35%, with 36% of the female dogs observed to be lactating. About 83% of the stray dogs were found to be healthy, while the remaining 17% suffered from injuries, skin infections, or other visible ailments.Madurai corporation has now announced plans to intensify sterilization and population control efforts at hotspots. Officials say the data will guide the future rollout of Animal Birth Control (ABC) and Anti-Rabies Vaccination (ARV) programmes across the city.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scroll.in
44 minutes ago
- Scroll.in
Heart and kidney diseases, cancer: What else can GLP-1 drugs treat in addition to obesity?
Research into the sugar-lowering powers of incretin hormones led to the discovery of GLP-1 drugs [like Ozempic and Mounjaro]. The added bonus of weight loss was serendipity. There seem to be many happy side effects of GLP-1 drugs. Of course, many of them are not because of the drugs themselves but because of weight loss. When you lose weight – whether through diet and exercise, bariatric surgery, or GLP-1 drugs – your knee pain and inflammation will reduce, heart health will improve, and so on. Yet it seems that GLP-1 drugs are directly improving health outcomes as well, apart from the benefits that accrue by reducing blood sugar and hunger. Dr Daniel Drucker, one of the scientists who discovered the GLP1 hormone, conducted an experiment on mice with systemic inflammation. When treated with GLP-1 drugs, the inflammation decreased. However, if the drug was blocked from reaching the brain, the inflammation did not reduce. This suggests that the brain plays a critical role in inflammation, and that reducing it may be directly mediated through the brain and not just indirectly due to weight loss. GLP-1 receptors – the switches activated by the drug – are found in the heart, liver, kidneys, pancreas, stomach, intestines and brain. As with many hormones, GLP-1's effects may not be limited to hunger and satiety alone but may also have multiple other functions. The full range of benefits these drugs can have in treating various diseases is still being discovered. In October 2018, Novo Nordisk, the company that holds the patent for semaglutide, began a trial to study the impact of the drug on the cardiovascular health of people who had heart disease and were overweight or obese but did not have diabetes. They enrolled over 17,000 people from diverse backgrounds. Their mean BMI was 33, and nobody was less than BMI 27. They were divided into two similar groups. One was given semaglutide (Wegovy) and the other was given a placebo. As the trial progressed, Covid-19 struck. Both groups saw similar rates of infection. Among the 184 who died of Covid-19, 78 had been taking semaglutide and 106 were on placebo. The difference is significant enough to suggest that the drug helped save some lives. In the trial, some died of reasons other than the pandemic. After accounting for all causes of death, those taking the drug saw 19 per cent fewer fatalities. No, this does not mean that GLP-1 drugs can be a treatment for Covid-19. What it does show is that the drug is improving overall health through weight loss and reduced inflammation. It confirms what we know about obesity: It's a disease. Did some of those patients survive the pandemic only because weight loss improved their overall health, or also because the drug reduced their inflammation levels, or were there more reasons? This is an open question because scientists are still discovering the full range of what GLP-1 drugs do inside the body. Their action on various diseases could help understand the disease better, perhaps aiding the discovery of new specific drugs and treatments for those diseases. GLP-1 drugs themselves could, some day, be prescribed for many of those conditions. It is important to note that research is ongoing and incomplete. Patients should not self-medicate. Even if GLP-1 drugs are approved by the US FDA or other regulators for some of these conditions, they must be used only under medical supervision. Here are some medical conditions in which GLP-1 drugs have been found to be helpful so far. Heart disease In March 2024, the US FDA approved Wegovy (semaglutide, same as Ozempic) for patients who had heart disease along with obesity or were overweight even if they did not have diabetes. This followed a large trial called SELECT (the same trial that showed the Covid-19 effect fortuitously), which had 17,600 patients enrolled in two groups. In the placebo group, 8 per cent of participants saw major adverse cardiovascular events (MACEs), such as heart attack, stroke or cardiovascular death. In the group taking semaglutide, the incidence was 6.5 per cent. That's a nearly 20 per cent reduction in risk. While this trial used weekly injectable semaglutide, the more recent SOUL trial, involving almost 10,000 participants, used oral semaglutide (Rybelsus) and showed a reduction in MACE of 14 per cent. Statins remain the main drug for people with heart disease, but these results demonstrate the role of semaglutide in the prevention of heart disease on top of statin therapy. Tirzepatide (GIP + GLP-1) has also been shown to reduce cardiovascular risk. In an international trial of 713 adults in nine countries, including the US, called the SUMMIT trial, participants with heart failure taking tirzepatide for two years had significantly improved cardiovascular health and reduced progression of heart failure. An analysis of 13 GLP-1 drug trials comprising more than 80,000 patients showed significant reductions in MACE, overall and cardiovascular mortality, stroke, and need for coronary procedures like angioplasty and surgery, regardless of the presence of diabetes. The benefits could not be explained by weight loss alone. These trials have led to guidelines that all people with diabetes and/or obesity who either suffer from or are at risk of heart disease should be treated with GLP-1 drugs. However, since people with diabetes and/or obesity are at higher risk of heart attack and stroke anyway, it is prudent to consider the prescription of these drugs in most people with diabetes even if they have no evidence of heart disease. Chronic kidney disease In January 2025, the US FDA approved the use of semaglutide in patients who have both diabetes and kidney disease. Our kidneys filter out toxins from the body and pass them through the urine. Their ability to do so starts declining in patients with diabetes. The FLOW trial showed that for patients with both type 2 diabetes and chronic kidney disease, taking semaglutide lowered the risk of complications (dialysis, need for transplant) by 24 per cent. It also slowed down the decline of their kidney function. Moreover, in a post hoc analysis of the SURPASS-4 randomised clinical trial, tirzepatide decreased protein excretion, slowed decline in kidney function and reduced death due to kidney causes in patients with type 2 diabetes. Cancer Since obesity raises the risk of some types of cancer, it is not surprising that studies have started finding a reduced incidence of cancer among those taking GLP-1 drugs. This is similar to the reduced risk of cancer seen among those who have undergone bariatric surgery. Obesity-related cancers are concentrated around the metabolic organs and, among women, around the reproductive organs as well. An observational study of 1.65 million patients in the US found a reduced risk of ten types of obesity-related cancers among diabetes patients taking GLP-1 drugs as compared to those on insulin. Another study found the risk of 13 types of cancer reduced by 22 per cent in those who underwent bariatric surgery and by 39 per cent among those who took GLP-1 drugs. Excerpted with permission from The Weight Loss Revolution, Ambrish Mithal and Shivam Vij, Juggernaut.
NDTV
44 minutes ago
- NDTV
What Are Animal Birth Control Rules That Top Court Called "Absurd" Over Stray Dog "Menace"
New Delhi: The Supreme Court on Monday directed the Delhi government and civic bodies to start picking up stray dogs from all localities at the earliest and keep them at dog shelters, an order that came amid a rise in cases of dog bites and deaths due to rabies. A bench of Justices JB Pardiwala and R Mahadevan also said the Animal Birth Control (ABC) Rules, 2023, are "absurd". According to the rules, a stray dog is picked up from a locality, and is sterilised and sent back to the same locality. "Pick up dogs from all localities and shift them to shelter homes. For the time being, forget the rules," the bench said. They also said the situation was "extremely grim". "Immediate steps need to be taken to take care of the menace of dog bites leading to rabies," the bench said. The top court said that children should not, at any cost, fall prey to stray dog bites leading to rabies. "We are issuing these directions keeping the larger public interest in mind." What Are Animal Birth Control (ABC) Rules, 2023 The Animal Birth Control (ABC) Rules, 2023, are a set of guidelines issued by the Centre to manage stray dog populations. They focus on sterilising and vaccinating stray dogs to control their numbers and prevent the spread of rabies. They were formed to address human-dog conflicts and promote animal welfare. The Supreme Court said the dog shelters should be created to accommodate around 5,000 stray dogs, and sufficient personnel should be deployed there to sterilise and immunise the canines. The top court also sought a reply from authorities on coming up with shelter homes within eight weeks. The court also warned that if any person or organisation comes in the way of the picking up of stray dogs by the authorities, strict action will be taken against them. It also directed the authorities to create a helpline within a week so that all dog bite cases are reported immediately. Over 37 Lakh Dog Bite Cases In India In 2024 The Centre last month said that India reported over 37 lakh dog bite cases and 54 suspected human rabies deaths in 2024. According to data shared by Union Minister SP Singh Baghel in the Parliament on July 22, the total number of dog bite cases stood at 37,17,336, while the total 'suspected human rabies deaths' were 54 last year. He said that municipalities are responsible for controlling the stray dog population, adding that they are implementing the Animal Birth Control Programme to regulate their population. Elaborating on the steps, he said his ministry issued an advisory in November 2024 to states, asking them to implement the ABC Programme and related activities through local bodies, as part of its objective to ensure the "safety and security of children, especially toddlers, from stray dog attacks".
New Indian Express
3 hours ago
- New Indian Express
Guntur GGH to offer free liver transplants
GUNTUR: Guntur Government General Hospital (GGH) is set to become the first government hospital in Andhra Pradesh to offer free liver transplantation surgeries to economically disadvantaged patients. The surgeries are expected to begin by October, while free knee replacement procedures will resume by mid-August after a prolonged interval. This initiative marks a significant milestone for public healthcare in the state. With the recent issuance of the Jeevandan AP Deceased Donor Certificate, GGH is now authorized to perform organ transplants using organs from deceased donors. Patients registered for liver transplants will be treated based on a waiting list to ensure transparency and fairness. Speaking to TNIE, GGH Superintendent Dr. SSV Ramana confirmed that the groundwork is nearly complete. 'Both knee and liver transplant surgeries will commence shortly, restoring access to life-saving treatment for patients unable to afford private care,' he said. To support this initiative, the hospital has set up two dedicated operation theaters at a cost of Rs.10 lakh and appointed three transplant coordinators. A team of specialists in general medicine, hepatology, anesthesia, and surgery has undergone intensive training under the guidance of Dr. Rajnikanth, a senior liver transplant expert from Chennai. GGH performs 22 kidney transplants Awareness campaigns have also been launched to promote organ donation, although only deceased donor transplants are currently permitted. GGH has a track record of performing complex surgeries, including a successful heart transplant in 2016, the first of its kind in a state-run facility. Since then, the hospital has performed 22 kidney transplants and several knee replacements. However, all transplant services were suspended during the COVID-19 pandemic and have not resumed until now. The liver transplant program, which was long in the pipeline, was delayed due to administrative and logistical hurdles. With approvals and infrastructure now in place, officials say the hospital is finally ready to offer this critical service to the underprivileged.
